Association of imipenem/cilastatin with development of acute kidney injury in critically ill patients requiring carbapenem treatment
A retrospective cohort study analyzing data from three large ICU databases found no significant overall association between imipenem/cilastatin treatment and a reduced risk of acute kidney injury compared to non-cilastatin carbapenems in critically ill patients, despite some conflicting results in individual datasets.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body is a bustling city, and your kidneys are the master filtration plants that keep the water clean and the streets free of toxic sludge. Sometimes, when the city is under attack by a massive infection or a severe injury, the filtration plants get overwhelmed and start to break down. This breakdown is called Acute Kidney Injury (AKI). It's a scary situation for patients in the Intensive Care Unit (ICU), where the stakes are incredibly high. To fight these infections, doctors often use powerful antibiotics called carbapenems. Think of these drugs as heavy-duty demolition crews that smash bacteria, but sometimes, in their zeal, they accidentally knock a few bricks out of the kidney's filtration plant.
For decades, scientists have been trying to build a "safety shield" for these kidneys. One such shield is a molecule called cilastatin. In animal studies, cilastatin acted like a bodyguard, stopping the kidney from breaking down the antibiotic and protecting the filtration plant from damage. Because of this, cilastatin is usually sold only in a special team-up with a specific antibiotic called imipenem. The big question for doctors has been: Does this bodyguard actually work in real human patients in the ICU, or is it just a great idea that works only in the lab?
This paper is a massive detective story that tried to answer that question by looking at the medical records of nearly 4,000 critically ill patients across three huge databases. The researchers wanted to see if patients who got the "shielded" antibiotic team (imipenem/cilastatin) had fewer kidney failures than those who got other, similar antibiotics without the shield. They used a clever statistical trick called "overlap weighting" to make sure they were comparing apples to apples, adjusting for things like how sick the patients were before they even got the drugs.
The results were a bit of a plot twist. In one of the older databases (MIMIC-III), the team found that patients with the shielded antibiotic did seem to have a lower chance of developing kidney injury—about half as likely as those without it. However, when they looked at two other, more recent databases (MIMIC-IV and AUMC), the story changed completely. In these groups, the shielded antibiotic offered no extra protection; the risk of kidney injury was exactly the same whether patients got the shield or not. When the researchers combined all the data together, the overall conclusion was that the shield didn't make a significant difference in the real world of the ICU.
The authors suggest that the "magic" seen in the older data might have been a fluke or due to differences in how patients were treated back then, perhaps because medical practices have improved over the years. They also point out a crucial detail: the dose of cilastatin used in the animal studies that showed such great protection was 5 to 10 times higher than the dose approved for humans. It's like testing a parachute on a toy plane and then expecting it to save a jet pilot; the scale matters.
Ultimately, the study suggests that for critically ill patients today, using the imipenem/cilastatin combination does not appear to lower the risk of kidney injury compared to other carbapenem antibiotics. While the idea of a kidney-protecting shield is still exciting, this specific combination doesn't seem to be the silver bullet for preventing kidney failure in the ICU, at least not at the doses we are currently using. The door remains open for future research to see if higher doses or different patient groups might still benefit, but for now, doctors shouldn't expect this specific drug pair to be a guaranteed safety net for kidneys.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.